Guggenheim Begins Coverage on Emergent Biosolutions (NYSE:EBS)

Guggenheim initiated coverage on shares of Emergent Biosolutions (NYSE:EBS) in a research note released on Thursday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $65.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on the stock. ValuEngine upgraded shares of Emergent Biosolutions from a hold rating to a buy rating in a research report on Wednesday, September 4th. Laidlaw set a $72.00 price objective on shares of Emergent Biosolutions and gave the company a buy rating in a research note on Wednesday, September 4th. Wells Fargo & Co raised shares of Emergent Biosolutions from a market perform rating to an outperform rating and raised their price objective for the company from $61.00 to $64.00 in a research note on Wednesday, September 4th. Cowen reissued a hold rating and issued a $60.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, July 31st. Finally, Chardan Capital set a $71.00 price objective on shares of Emergent Biosolutions and gave the company a buy rating in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $70.25.

Shares of EBS opened at $52.00 on Thursday. Emergent Biosolutions has a 1-year low of $39.11 and a 1-year high of $73.89. The stock has a market cap of $2.79 billion, a PE ratio of 22.32, a P/E/G ratio of 0.88 and a beta of 1.56. The firm has a 50-day simple moving average of $45.61 and a two-hundred day simple moving average of $47.94. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.30 and a quick ratio of 1.53.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04). Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The company had revenue of $243.20 million for the quarter, compared to analyst estimates of $217.94 million. During the same quarter in the prior year, the business earned $1.07 earnings per share. Emergent Biosolutions’s revenue was up 10.4% on a year-over-year basis. As a group, sell-side analysts expect that Emergent Biosolutions will post 3.06 earnings per share for the current fiscal year.

In other news, Director Kathryn C. Zoon sold 1,509 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $56.12, for a total value of $84,685.08. Following the completion of the transaction, the director now owns 21,494 shares of the company’s stock, valued at $1,206,243.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 14.10% of the company’s stock.

A number of institutional investors have recently modified their holdings of EBS. Earnest Partners LLC lifted its stake in Emergent Biosolutions by 860.6% in the second quarter. Earnest Partners LLC now owns 1,692,171 shares of the biopharmaceutical company’s stock worth $81,749,000 after acquiring an additional 1,516,013 shares during the last quarter. Neuberger Berman Group LLC lifted its stake in Emergent Biosolutions by 47.3% in the first quarter. Neuberger Berman Group LLC now owns 1,922,108 shares of the biopharmaceutical company’s stock worth $97,105,000 after acquiring an additional 617,486 shares during the last quarter. Vaughan Nelson Investment Management L.P. purchased a new position in Emergent Biosolutions in the first quarter worth approximately $26,644,000. The Manufacturers Life Insurance Company lifted its stake in Emergent Biosolutions by 1,633.3% in the first quarter. The Manufacturers Life Insurance Company now owns 474,247 shares of the biopharmaceutical company’s stock worth $23,959,000 after acquiring an additional 446,886 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in Emergent Biosolutions by 197.0% in the second quarter. Jennison Associates LLC now owns 562,121 shares of the biopharmaceutical company’s stock worth $27,156,000 after acquiring an additional 372,857 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Read More: What are catch-up contributions?

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.